Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S100Apt-EVs
- Development stage
- Preclinical
- Lead developer
- Shanghai Jiao Tong University
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Implant
01
Overview
S100Apt-EVs are preclinical engineered extracellular vesicles (EVs) derived from adipose-derived stem cells (ASCs) and functionalized with an S100 protein aptamer (S100Apt) chemically grafted onto their surface. Developed by researchers at Shanghai Jiao Tong University, these neuro-targeted vesicles are designed to specifically target Schwann cells to promote neuroregeneration and prevent postoperative fibrosis. In preclinical models, S100Apt-EVs are delivered via an anionic hyaluronic acid-based (HAD) hydrogel (forming the 'HAD-AptEV' hydrogel or 'shield-spear' biological patch) for suture-free bladder reconstruction and nerve repair. Upon targeting Schwann cells, S100Apt-EVs stimulate the secretion of brain-derived neurotrophic factor (BDNF), which downregulates the pro-fibrotic TGF-β/Smad signaling pathway and inhibits lysyl oxidase (LOX)-mediated matrix crosslinking, thereby enabling functional, fibrosis-free tissue regeneration.
- Other names
- S100 aptamer-modified extracellular vesiclesS-100 aptamer-modified extracellular vesiclesS 100 aptamer-modified extracellular vesiclesS100Aptamer-EVsS-100Aptamer-EVsS 100Aptamer-EVs
02
Targets
Ca signaling (Calcium signaling family)
Beyond the preview
Go deeper on S100Apt-EVs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S100Apt-EVs.